Eli Lilly's stock rises after its Zepbound weight-loss drug achieved better results than rival Wegovy in a head-to-head trial
Eli Lilly & Co. Inc.'s stock (LLY) rose 2% early Wednesday, after the company said a study comparing its Zepbound weight-loss drug to rival Novo Nordisk's Wegovy showed an average weight loss of 20.2% ...
Why Amgen’s MariTide could rival Eli Lilly, Novo Nordisk’s obesity drugs
Unlike its rivals, which require weekly injections, MariTide offers the potential for monthly or less frequent dosing ...
Lilly’s Zepbound Beats Novo’s Wegovy in First Head-to-Head Trial
Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S’s Wegovy in the first head-to-head ...
Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%
Eli Lilly and Company (NYSE: LLY) today announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical ...
Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial
Zepbound’s greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of ...
This weight loss drug helped people shed more pounds than Wegovy, new trial results show
People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a clinical ...
Lilly's Zepbound tops Wegovy for weight loss in head-to-head trial
Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo ...
Eli Lilly’s Zepbound Beats Novo Nordisk’s Wegovy in First Head-to-Head Study
People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s ...
Ibj.com1h
Trial shows Lilly’s Zepbound helps patients lose far more weight than competing drug
Eli Lilly and Co. said its weight-loss treatment Zepbound helped patients lose 47% more relative weight than competitor Novo ...
Weight-loss drugs deliver life-changing health benefits - and big profits
State measures now seek to remove barriers to weight-loss drugs, as demand for the meds skyrockets amid rising concerns about ...
Becker's Hospital Review1d
GLP-1s and heart outcomes: 5 recent findings
With deaths from obesity-related heart disease reportedly increasing by 180% over the past 20 years, more research is being done to learn how GLP-1 medications such as Ozempic, Wegovy, Mounjaro and ...
BioPharma Dive1d
Diabetes advocacy group discourages use of compounded GLP-1 drugs
The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that ...